IRWD Positive Sentiment
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week
Key Takeaway: Ironwood Pharmaceuticals has announced positive final data from its Phase II STARS Nutrition study, which evaluated Apraglutide for Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC). The results were presented at the United European Gastroenterology Week, highlighting the drug's potential efficacy in this patient population. This marks a significant advancement in treatment options for SBS-IF.
Price reaction · baseline $9.35 (2023-10-13 close) · clean, no other IRWD news in the window
day 0 close · peak
+4.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Positive final data from the STARS Nutrition study.
- Demonstrated efficacy of Apraglutide in treating SBS-IF.
- Presentation at a significant gastroenterology event.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+57%
120-day peak, hindsight
Typical move
3.8%
average across 2 past catalysts
Lead asset
IW-3718
Phase 3 · Gastroesophageal Reflux Disease (GERD)
Frequently Asked Questions
What is the STARS Nutrition study?
The STARS Nutrition study is a Phase II clinical trial evaluating Apraglutide for Short Bowel Syndrome with Intestinal Failure.
What were the results of the STARS study?
The study reported positive final data, indicating the efficacy of Apraglutide in treating SBS-IF.
Where was the data presented?
The data was presented at the United European Gastroenterology Week.
What condition does Apraglutide target?
Apraglutide targets Short Bowel Syndrome with Intestinal Failure.